| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -10 | -10 | 120 | 0 | 0 |
| Net Income Growth | unch | -108.33% | unch | unch | +100.00% |
Lotus Pharms Inc (LTUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lotus Pharmaceuticals, Inc. operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd., collectively Lotus East. The Company believes Lotus East has some of the most advanced pharmaceutical production equipment in China and its manufacturing facilities meet national Good Manufacturing Practices. The Company distributes its own portfolio of drugs and pharmaceutical products produced by other manufacturers in the People's Republic of China through an extensive national distribution network. Liang Fang owns and operates drug stores throughout Beijing, China that sell Western and traditional Chinese medications and lease medical treatment facilities to licensed physicians. En Zhe Jia is a manufacturer for Liang Fang and maintains facilities for the production of medicines, Chinese medicine, as well as the research and production of other new medicines.
Fiscal Year End Date: 12/31